Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5249-5256

  Rammos, Christos ^a   Hendgen Cotta, Ulrike B ^a   Sobierajski, Julia ^a   Adamczyk, Sarah ^a   Hetzel, Gerd R ^b   Kleophas, Werner ^b   Dellanna, Frank ^b   Kelm, Malte ^a   Rassaf, Tienush ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Nephrology Practice   (Germany)

Author keywords

End stage renal disease; Endothelial dysfunction; Macrophage migration inhibitory factor; Vascular stiffness

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROPHAGE MIGRATION INHIBITION FACTOR; STEROID; TROPONIN I;

AGE; AGED; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; AUGMENTATION INDEX; BODY WEIGHT; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART MUSCLE INJURY; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MORBIDITY; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PULSE PRESSURE; SEX DIFFERENCE; TONOMETRY; VASODILATATION;

END-STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; MACROPHAGE MIGRATION INHIBITORY FACTOR; VASCULAR STIFFNESS;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY FAILURE, CHRONIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; TROPONIN; VASCULAR STIFFNESS; VASODILATION;

EID: 84887189404     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.021     Document Type: Article

References (39)

1. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
2. W.G. Goodman, J. Goldin, and B.D. Kuizon Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 2000 1478 1483
3. G.M. London, S.J. Marchais, A.P. Guerin, F. Metivier, and H. Adda Arterial structure and function in end-stage renal disease Nephrol Dial Transplant 17 2002 1713 1724
4. M.E. Safar, J. Blacher, and B. Pannier Central pulse pressure and mortality in end-stage renal disease Hypertension 39 2002 735 738
5. G.M. London, J. Blacher, B. Pannier, A.P. Guerin, S.J. Marchais, and M.E. Safar Arterial wave reflections and survival in end-stage renal failure Hypertension 38 2001 434 438
6. J.J. Oliver, and D.J. Webb Noninvasive assessment of arterial stiffness and risk of atherosclerotic events Arterioscler Thromb Vasc Biol 23 2003 554 566
7. J. Yeboah, J.R. Crouse, F.C. Hsu, G.L. Burke, and D.M. Herrington Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study Circulation 115 2007 2390 2397
8. P. Stenvinkel Inflammation in end-stage renal disease: the hidden enemy Nephrology (Carlton) 11 2006 36 41
9. C. Wanner, V. Krane, and W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
10. C.N. Marti, M. Gheorghiade, A.P. Kalogeropoulos, V.V. Georgiopoulou, A.A. Quyyumi, and J. Butler Endothelial dysfunction, arterial stiffness, and heart failure J Am Coll Cardiol 60 2012 1455 1469
11. S.N. Breit, J.J. Carrero, and V.W. Tsai Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease Nephrol Dial Transplant 27 2012 70 75
12. H. Flaster, J. Bernhagen, T. Calandra, and R. Bucala The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity Mol Endocrinol 21 2007 1267 1280
13. J. Bernhagen, R. Krohn, and H. Lue MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment Nat Med 13 2007 587 596
14. A. Burger-Kentischer, H. Goebel, and R. Seiler Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis Circulation 105 2002 1561 1566
15. C.M. Yu, C.P. Lau, K.W. Lai, X.R. Huang, W.H. Chen, and H.Y. Lan Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction Am J Cardiol 88 2001 774 777
16. I.I. Muller, K.A. Muller, and H. Schonleber Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response PLoS One 7 2012 e38376
17. N. Petrovsky, L. Socha, D. Silva, A.B. Grossman, C. Metz, and R. Bucala Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator Immunol Cell Biol 81 2003 137 143
18. M. Totzeck, U.B. Hendgen-Cotta, and C. Rammos Higher endogenous nitrite levels are associated with superior exercise capacity in highly trained athletes Nitric Oxide Biol Chem 27 2012 75 81
19. T. Rassaf, C. Heiss, and S. Mangold Vascular formation of nitrite after exercise is abolished in patients with cardiovascular risk factors and coronary artery disease J Am Coll Cardiol 55 2010 1502 1503
20. C. Heiss, C. Meyer, and M. Totzeck Dietary inorganic nitrate mobilizes circulating angiogenic cells Free Radic Biol Med 52 2012 1767 1772
21. J. Balzer, T. Rassaf, and C. Heiss Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial J Am Coll Cardiol 51 2008 2141 2149
22. T. Rassaf, C. Heiss, and U. Hendgen-Cotta Plasma nitrite reserve and endothelial function in the human forearm circulation Free Radic Biol Med 41 2006 295 301
23. J. Sobierajski, U.B. Hendgen-Cotta, and P. Luedike Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels Free Radic Biol Med 63C 2013 236 242
24. A.L. Pauca, M.F. O'Rourke, and N.D. Kon Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform Hypertension 38 2001 932 937
25. S. Laurent, J. Cockcroft, and L. Van Bortel Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 27 2006 2588 2605
26. A. Makino, T. Nakamura, and M. Hirano High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus Atherosclerosis 213 2010 573 578
27. P. Luedike, U.B. Hendgen-Cotta, and J. Sobierajski Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory factor Circulation 125 2012 1880 1889
28. A. Bruchfeld, J.J. Carrero, and A.R. Qureshi Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation Mol Med 15 2009 70 75
29. C. Meyer, C. Heiss, and C. Drexhage Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function J Am Coll Cardiol 55 2010 454 459
30. Q. Cheng, S.J. McKeown, and L. Santos Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules J Immunol 185 2010 1238 1247
31. J.H. Pan, G.K. Sukhova, and J.T. Yang Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice Circulation 109 2004 3149 3153
32. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
33. S. Fichtlscherer, G. Rosenberger, D.H. Walter, S. Breuer, S. Dimmeler, and A.M. Zeiher Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease Circulation 102 2000 1000 1006
34. F.U. Mattace-Raso, T.J. van der Cammen, and I.M. van der Meer C-reactive protein and arterial stiffness in older adults: the Rotterdam Study Atherosclerosis 176 2004 111 116
35. S.S. DeLoach, and R.R. Townsend Vascular stiffness: its measurement and significance for epidemiologic and outcome studies Clin J Am Soc Nephrol 3 2008 184 192
36. C.M. McEniery, Yasmin, and I.R. Hall Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT) J Am Coll Cardiol 46 2005 1753 1760
37. N.A. Khan, B.R. Hemmelgarn, M. Tonelli, C.R. Thompson, and A. Levin Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis Circulation 112 2005 3088 3096
38. G.F. Mitchell, J.A. Vita, and M.G. Larson Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study Circulation 112 2005 3722 3728
39. D. Qi, X. Hu, and X. Wu Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion J Clin Invest 119 2009 3807 3816